Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Lymphoproliferative Disorders and Chemokines

Author(s): V. Pistoia, A. Corcione, F. Dallegri and L. Ottonello

Volume 7, Issue 1, 2006

Page: [81 - 90] Pages: 10

DOI: 10.2174/138945006775270187

Price: $65

Abstract

Chemokines are low molecular weight cytokines specialized in leukocyte recruitment. Recent studies have shown that tumor cells of hematopoietic and non hematopoietic origin express different chemokine receptors that may be involved in neoplastic cell growth, metastasis and angiogenesis. Human lymphoproliferative disorders arise from the malignant transformation of normal lymphoid cells frozen at discrete maturational stages. Studies performed with acute or chronic lymphoproliferative disorders have shown that CXCR4, the unique receptor for CXCL12, is up-regulated in many B and T cells malignancies and may be involved in metastatic localization of the neoplastic elements. Additional chemokine receptors are expressed in the individual lymphoproliferative disorders, but some of these are often non functional. Here we shall review the state of the art on chemokine receptor expression and function in human lymphoproliferative disorders, stressing the potential value of chemokines receptors as novel therapeutic targets. In this respect, small antagonistic peptides are being produced by pharmaceutical companies and hold great promise for clinical application.

Keywords: Tumor, chemokine receptors, lymphoproliferative disorder, osteoclast activation, Multiple Myeloma, immunophenotype

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy